Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking approach to diabetes management. These innovative medications operate by mimicking the inherent actions of GLP-1, a hormone released by the gut in response to consumption. By triggering GLP-1 receptors in the pancreas, these compounds enhance insulin production and su

The burgeoning landscape of emerging treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting substantial weight reduction – they exhibit intriguing contrasts i